Natalie de Graaf, from the API Innovation Center, discusses a recent whitepaper detailing areas where the generic drugs pipeline is under stress.
Natalie de Graaf
Advertisement
Natalie de Graaf is VP and GM of Data, AI and ML; Solutions for Health and National Security at the API Innovation Center.
Articles by Natalie de Graaf
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics, Madrigal Enters Licensing Agreement for ARO-PNPLA3
2
From Insight to Impact: Making Real-World Evidence Actionable in Urology
3
Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial
4
The Past, Present, and Future Innovation of Cardinal Health 3PL Services and Packaging Solutions
5